Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod
Metadatos
Mostrar el registro completo del ítemAutor
Piñar Morales, Raquel; Carrasco Garcia, María; Gutiérrez Rojas, Luis; Barrero Hernández, Francisco JavierEditorial
S. Karger AG
Materia
Fingolimod Immune reconstitution inflammatory syndrome Magnetic resonance imaging Multiple sclerosis Progressive multifocal leukoencephalopathy
Fecha
2022-02-07Referencia bibliográfica
Morales, R. P., Garcia, M. C., Gutierrez-Rojas, L., & Hernández, F. J. B. (2022). Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod. Case Reports in Neurology, 14, 38-43. [https://doi.org/10.1159/000521944]
Resumen
Progressive multifocal leukoencephalopathy (PML) is a rare complication of immunosuppressive treatment in MS patients. Immune reconstitution inflammatory syndrome (IRIS) appears after the withdrawal of certain drugs such as natalizumab (NTZ) or fingolimod. The development of PML-IRIS after NTZ treatment has been described, and its diagnosis is made by clinical and radiological criteria and the determination of the John Cunningham virus in CSF. We present a clinical case of a patient with MS who, after the withdrawal of fingolimod, developed PML-IRIS despite sustained lymphopenia. This is important for pharmacovigilance purposes, not only for NTZ but also for alternative drugs used in MS treatment.